Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probiotics + Disitamab Vedotin + Toripalimab in MIBC
NCT07474064Phase 2Not yet recruiting
- Sponsor
- Chenxu (Shanghai) Biotechnology
- Start
- Mar 2026
- Primary completion
- Mar 2031
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised trial of clostridium butyricum in muscle-invasive bladder cancer (MIBC) (2 arms), sponsored by Chenxu (Shanghai) Biotechnology. Primary endpoint: Bladder-Intact Event-Free Survival at 3 years. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
clostridium butyricum
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07474064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07474064.